1. An important reference citing previous characterization of Acm1 and its pseudosubstrate degron sequences has been omitted and should be added (Choi et al 2008. J Biol Chem 283: 23701-10) . This reference should actually replace the Hall et al reference cited in 2 places (page 4 line 22 and page 16 line 16) and the Martinez et al reference cited on page 5 line 24. At the top of page 11, this reference should be added along with the Enquist-Newman at al reference for demonstration that db3 and ken mutations lead to increased Acm1 ubiquitination.
2. The observation that ubiquitination in the absence of DB3 and KEN is contradictory to the results in 2 previous reports (Enquist-Newman et al 2008 and Choi et al 2008) that show removal of the Nterminus containing DB1 actually increases ubiquitination of Acm1 lacking DB3 and KEN. This discrepancy should at least be noted and should probably be considered in devising the model that Acm1 is recognized via DB1 for poly-ubiquitination when DB3 and KEN are not present. Similarly, previous findings showed that Acm1 could be fairly efficiently conjugated to ubiquitin but that extension to polyubiquitin chains was inefficient unless mutations were introduced into DB3 and KEN (Choi et al 2008) . This observation seems inconsistent with a significant role for lysine placement in determining substrate/pseudosubstrate identity and should be addressed in the discussion.
3. Enquist-Newman et al also found evidence for an additional sequence element between residues 60 and 70 that contribute to Acm1 interaction with Cdh1 and therefore overlaps with the A motif described here. This previous finding should be cited. This does not decrease the impact and significance of the current work because Burton et al have identified the specific residues in this regions and their contact sites on Cdh1, and have characterized the role of these residues in Cdh1 binding and inhibition in much greater depth.
4. In several places in the paper the authors conclude that residues or regions in Acm1 are "important for Cdh1 inhibition in vivo". Although it may be primarily a semantic issue, it is still unclear if Acm1 makes a significant and important contribution to APC-Cdh1 inhibition in vivo. It CAN inhibit APC-Cdh1 in vivo using artificial experimental conditions. It is probably more technically correct at this point to say that these residues/motifs "can contribute to Cdh1 inhibition in vivo" or even better to specify that they are important "in an in vivo assay for Acm1 inhibitory activity". Again, this doesn't change any of the conclusions but may help avoid misleading readers. 5. On page 11 the authors appear to conclude that the affinity of the Cdh1-Acm1 interaction does not directly determine ability to be ubiquitinated based on their observation that mutations in the A motif do not lead to an increase in Acm1 ubiquitination in vitro. However, this may be too simplistic a conclusion and has not really been rigorously explored. For example, single mutations in either DB3 or KEN also do not significantly increase Acm1 ubiquitination even though they have effects on binding affinity. The A motif mutation alone simply may not decrease affinity enough to see an effect. It would be interesting to explore A motif mutations in combination with other mutations such as DB3, KEN, or the J and K motifs, to see if further decreasing affinity in different ways is sufficient to allow efficient ubiquitination. Thus, a firm conclusion of this nature would require a more thorough investigation of mutant combinations and I would recommend that this conclusion based on the current data be tempered by acknowledging that it is not necessarily incompatible with the model for binding affinity controlling ubiquitination.
6. It is a bit unclear what the significance of the lysine addition experiment is. Although the addition of lysines at positions 83 and 84 clearly lead to an increase in ubiquitin conjugation in vivo, it does not necessarily mean that Acm1 has been converted to a substrate. This would require demonstrating APC-Cdh1-dependent turnover in vivo and targeting to the proteasome. This of course is technically challenging and I am not suggesting it is necessary to show this. However, this conclusion also should probably include a cautionary note that the increase in detectable ubiquitination does not prove that Acm1 is now being processed like a substrate. On this same note, although the 83/84 lysine insertion experiment is nicely controlled with the arginine mutations it is still conceivable that these mutations could affect the interaction between Acm1 and Cdh1 (either directly or indirectly by perturbing overall structure or folding) and therefore lead to increased ubiquitination due to decreased binding. If the authors could do a quick control with these mutants in the 2-hybrid and/or in vitro binding assays to show affinity is not disrupted then the conclusions from these results would be more concrete. Regulation of the ubiquitin ligase APC/C occurs on many levels, including pseudosubstrate inhibition. Different mechanisms have been suggested to explain pseudosubstrate inhibition, but a consensus has not been reached. In this manuscript, Burton et al. investigate the binding motifs required for the interaction of the yeast pseudosubstrate inhibitor Acm1 with Cdh1, the substrate recruitment factor of the APC/C. They find sequence motifs, termed "A-motif" and "K-motif" that contribute to binding of Acm1 to Cdh1 and to the function of Acm1 as a pseudosubstrate inhibitor. Using a screening approach, they determine residues in Cdh1 that appear to be important for recognizing the A-motif. Finally, they suggest that Acm1 behaves as a pseudosubstrate inhibitor, because it lacks lysine residues in appropriate positions that could act as acceptor sites for ubiquitination. Eliminating lysine residues from a known APC/C-substrate, Hsl1, is proposed to create a pseudosubstrate inhibitor.
Overall, I found this paper being clearly written, and most experiments being carefully executed. As stated below, some of the conclusions made by the authors do not appear to be watertight, but further experiments might be able to address these issues during a revision. The ideas put forward in this manuscript are interesting for a larger audience both in the cell cycle and the proteolysis fields.
Issues to be addressed:
1. The introduction should cite more up-to-date reviews on the ubiquitination system. 2. Figure 2E : it is difficult to compare the different Acm1 mutants, as their inhibitory capacity was only analyzed in an end-point reaction, with a single (weakly described) Acm1 concentration. To better judge the relevance of the mutations for pseudosubstrate inhibition, a concentration dependency should be shown for all mutants. In addition, the activity of an mdb3mkb mutant needs to be shown.
3. Figure 3D : the sites for recognizing the D-box and "A-motif" are so close to each other that simultaneous binding, as suggested by the authors, seems difficult to be accomplished. The authors should test whether D-box and A-motif compete for Cdh1 binding or not.
4. Figure 4B : It needs to be shown that the AAmdb3mk mutant does not bind Cdh1, in the same assay as shown in Figure 2D . Otherwise, it is difficult to understand why the protein is not ubiquitinated.
5. Figure 4C : This figure is the only evidence in the main body of the paper that supports a subtitle "Converting Acm1 into an APC-substrate". The effects of adding lysines are minor and not convincing. The authors might try to improve this reaction by adding more lysine residues, or they can provide more specificity controls. They should also investigate whether Acm1-K83/84 is now degraded by APC/C-Cdh1 in cells. Finally, a control is required to show that introduction of these lysines doesn't change binding of Acm1 to Cdh1. At this point, I do not see compelling evidence that adding lysine residues is sufficient for creating an APC/C-substrate.
6. Figure 5 : The authors claim that Hsl1 is converted into a potent pseudosubstrate inhibitor by removing the lysine residues, but they do not show that in vitro it behaves in any way different than wt-Hsl1. If there isn't any difference between the molecules in vitro, then Hsl1-K-less might simply be a competitive inhibitor in cells that can't be removed, which is not a specific phenotype.
7. Figure 6 : If Acm1 K-less can't be purified, because it's misfolded, not much can be learned from Figure 6 . I would leave this figure out of the paper, it does not add much.
8. discussion: I think it is a bit of a stretch to call the two acidic residues involved in Cdh1 binding the "A-motif". It will confuse readers, i.e. since there is already an A-box in the literature. Moreover, a motif would seem something that should be found in other substrates/regulators as well -otherwise you don't need to find another name for describing just two residues. I would prefer if the authors refer to the relevant amino acids, and not use the term "A-motif".
9. The authors should add recent findings to their discussion that APC-substrates, at least in human cells, have motifs that promote the addition of the first ubiquitin (Jin et al., 2008 ). This appears to fit nicely to their lack of such sequences in pseudosubstrate inhibitors.
Referee #3 (Remarks to the Author):
In this manuscript Burton and Solomon report a thorough characterization of Acm1, a pseudosubstrate inhibitor of the APC/C co-activator Cdh1. Acm1 contains destruction and KEN boxes (Dand KEN-box, respectively). The authors discovered two additional regions of Acm1, the A-motif and the K-motif. These additional regions of Acm1 are required for the interaction of Acm1 with Cdh1, and determine the outcome of the interaction (inhibition of Cdh1 or ubiquitination of the substrate).
In general, the work is technically solid. With at least four or five distinct points of contact, the binding of Acm1 to Cdh1 is very complex, and the authors did a good job at partly disentangling this intricacy. Nevertheless, due to the complexity of the interaction, the manuscript does not come across as a light reading. My main concern is that the message brought about by the title, the unveiling of a mechanism, is partly overstated. It is interesting that the introduction of a pair of lysine residues within a segment of Acm1 comprised between the A-motif and the KEN-box leads to partial ubiquitination of Acm1. Yet, the mechanistic significance of this finding is uncertain and one can hardly claim that this interesting result demonstrates a mechanism. On the other hand, turning a substrate of Cdh1 into an inhibitor by removing acceptor lysine residues is a nice result. It is however the expected result, provided that lysines do not play a fundamental role in the interaction.
Overall, therefore, my impression is that this manuscript does not convey a general message, and that its interest is unlikely to trascend the specific community of people working on Acm1. The authors argue that structural analysis might eventually be required to understand the interaction and to guide further functional analysis, and I do agree with them.
Specific points Page 11
The authors report that the ubiquitination of Acm1-N128-mdb3mkb was virtually elimintated by mutation of DB1. Later in the same paragraph they report that Acm1 containing the A-motif but lacking DB1, DB3 and the KEN box could not prevent Hsl1 degradation in vitro and in vivo. How are we supposed to interpret these results?
Page 13 (and Figure 6) The authors create an Acm1 mutant named K-less. It is not really K-less, because it retains three lysines, one in the KEN box and two in the K-motif. The behavior of this mutant is paradoxical. It does inhibit Cdh1, yet it is unstable in vivo. This is an interesting observation, that probably
The authors argue that the binding site for the A-motif is distinct from the binding site for the D-box and the KEN box, but one of the residues they identify V534, immediately precedes G535, a residue that has been previously implicated in D-box binding.
Page 14
The authors argue that the interaction of the K-motif with Cdh1 is low-affinity, but they can measure this interaction in the two-hybrid assay, which means that the affinity cannot be that low.
Please add the position of molecular weight markers to all gels.
Please label residues on Figure 3D The following are our detailed responses to the reviewers. The reviewer comments are italicized whereas our responses are in roman type. For brevity, I've edited out summary comments from the reviewers while retaining all the text to which we were asked to respond. 1. An important reference citing previous characterization of Acm1 and its pseudosubstrate degron sequences has been omitted and should be added (Choi et al 2008. J Biol Chem 283: 23701-10 We now address this point in the Discussion by stating that different mutations in Acm1 may alter the orientation of binding to Cdh1. Furthermore, our experiment used point mutants in DB1, whereas the two previous studies (and our own results that we didn't include) found low-level ubiquitination when DB1 and the entire N-terminus of Acm1 were deleted. I have more faith in results with two amino acid changes than with larger deletions. The different Acm1mdb3mkb mutants (with different N-and C-terminal truncations) may bind to Cdh1 differently and thereby influence the level of ubiquitination by APCCdh1. We also down play the importance of DB1 by noting that it has no physiological significance in the degradation of WT Acm1 by APCCdh1.
Similarly, previous findings showed that Acm1 could be fairly efficiently conjugated to ubiquitin but that extension to polyubiquitin chains was inefficient unless mutations were introduced into DB3 and KEN (Choi et al 2008). This observation seems inconsistent with a significant role for lysine placement in determining substrate/pseudosubstrate identity and should be addressed in the discussion.
We would argue that mono-ubiquitination of lysine residues is suggestive of poor placement making the ubiquitination inefficient or non-processive. Clearly there are lysine residues in Acm1 that can become efficiently ubiquitinated (polyubiquitinated) when Acm1 is recognized by APCCdc20 via DB1, or by APCCdh1 after mutation of DB3 and the KEN box (in which case APCCdh1 also recognizes Acm1 via DB1, not via DB3 and the KEN box as in the inhibitory orientation). The lysine insertion mutations allow Acm1 to be ubiquitinated by APCCdh1 while still bound to it via DB3 and the KEN box.
Enquist-Newman et al also found evidence for an additional sequence element between residues 60 and 70 that contribute to Acm1 interaction with Cdh1 and therefore overlaps with the A motif described here. This previous finding should be cited. This does not decrease the impact and significance of the current work because Burton et al have identified the specific residues in this regions and their contact sites on Cdh1, and have characterized the role of these residues in Cdh1 binding and inhibition in much greater depth.
This point has been added and cited.
In several places in the paper the authors conclude that residues or regions in Acm1 are "important for Cdh1 inhibition in vivo". Although it may be primarily a semantic issue, it is still unclear if Acm1 makes a significant and important contribution to APC-Cdh1 inhibition in vivo.

It CAN inhibit APC-Cdh1 in vivo using artificial experimental conditions. It is probably more technically correct at this point to say that these residues/motifs "can contribute to Cdh1 inhibition in vivo" or even better to specify that they are important "in an in vivo assay for Acm1 inhibitory activity". Again, this doesn't change any of the conclusions but may help avoid misleading readers.
As suggested by the reviewer, we have changed these statements to indicate that Acm1 inhibited APCCdh1 in a particular assay in vitro or in vivo. The observation that Acm1-N128-mdb3mkb is ubiquitinated whereas mutation or removal of DB1 in this form of Acm1 significantly reduces the level of ubiquitination, argues that affinity cannot be the sole explanation. Furthermore, the K83K84 mutant is ubiquitinated by APCCdh1 in vitro even though there is no apparent loss of Cdh1-binding affinity. Thus we believe the level of ubiquitination is influenced by both binding affinity and by positioning of lysine residues that are available for multiple rounds of ubiquitin conjugation. Thus our theory is not incompatible with the affinity model, only that other factors such as lysine residue positioning are important as well. We try to bring across this point in the discussion of the updated manuscript. The statement of the reviewer (in bold) also is in agreement that a decrease in affinity does not necessarily result in an increase in the level of ubiquitination. Basically I feel we are in agreement with the reviewer on this issue. However, this conclusion also should probably include a cautionary note that the increase in detectable ubiquitination does not prove that Acm1 is now being processed like a substrate.
On page 11 the authors appear to conclude that the affinity of the Cdh1-Acm1 interaction does not directly determine ability to be ubiquitinated based on their observation that mutations in the
It is a bit
We no longer say that these mutations convert Acm1 into an APCCdh1 substrate, instead concluding that they allow Acm1 to be ubiquitinated in vitro. Indeed, the rate of ubiquitination appears to be too low to promote robust degradation of Acm1 in vivo.
On this same note, although the 83/84 lysine insertion experiment is nicely controlled with the arginine mutations it is still conceivable that these mutations could affect the interaction between Acm1 and Cdh1 (either directly or indirectly by perturbing overall structure or folding) and therefore lead to increased ubiquitination due to decreased binding. If the authors could do a quick control with these mutants in the 2-hybrid and/or in vitro binding assays to show affinity is not disrupted then the conclusions from these results would be more concrete.
We have performed both a two-hybrid assay and an in vitro binding assay that demonstrate that the mutant Acm1 proteins bind Cdh1 equivalently to wild-type Acm1 (see new Supplemental Figure 8 ).
Minor note: on page 11, last line of the first paragraph, "...not prevent Hsl1 degradation in vitro or in vivo" should read "...not prevent Hsl1 ubiquitination in vitro or degradation in vivo"
This correction has been made.
Referee #2:
1. The introduction should cite more up-to-date reviews on the ubiquitination system.
We have added a more recent review. Interestingly, there are few recent broad reviews of the ubiquitin system, with most reviews focusing more narrowly on specific aspects of ubiquitination.
2. Figure 2E: This assay is meant to depict a qualitative difference between the different Acm1 mutants rather than a quantitative one. Thus, we simply wanted to know what features of Acm1 were important for its function, not necessarily to quantitate their effects. We have now stated the amount of Acm1 added (1.0 µg) in the Figure 2 legend. We apologize for this omission. We have previously shown that Acm1-mdb3mkb had minimal inhibitory activity in this assay (Ostapenko et al., (2008) Mol Cell Biol 28: 4653-4664) .
3. Figure 3D: We are unclear why the reviewer feels that two motifs within Acm1 (the D-box and the A-motif) could not bind simultaneously to nearby residues on Cdh1. Nevertheless, we performed a competition experiment in a previous publication (Ostapenko et al., (2008) Mol Cell Biol 28: 4653-4664) . We found that a combination of D-box and KEN box peptides could completely block binding of an APC substrate (Hsl1) to Cdh1. However, these peptides could not prevent Acm1 from binding to Cdh1, presumably because it could bind via it's A-motif at the same time that the D-box peptide was bound to Cdh1. Figure 4B : It needs to be shown that the AAmdb3mk mutant does not bind Cdh1, in the same assay as shown in Figure 2D . Otherwise, it is difficult to understand why the protein is not ubiquitinated.
4.
The requested experiment showing that this mutant does not bind Cdh1 is shown in Figure 1C (lane 5) in the same assay as Figure 2D . Perhaps this was unclear because the lane was labeled as 'mdb' rather than 'mdb3' (which has now been corrected).
5. Figure 4C We have toned down the subtitle "Converting Acm1 into an APC-substrate" by adding "in vitro" to the subtitle as we only observed an increase in Acm1 ubiquitination in vitro. We have also stated that Acm1 K83K84 still behaves as a Cdh1 inhibitor in vivo since it is able to block Hsl1-Ura3 degradation. We therefore do not believe that it is efficiently degraded by APCCdh1 in cells.
We agree with the reviewer that more lysine insertions may result in more efficient ubiquitination but this would require extensive screening and is beyond the scope of this study. Our goal was not necessarily to convert Acm1 into a great APC substrate (though that would've been nice), but rather to see if an absence of appropriate lysines might be preventing any ubiquitination of Acm1 by APCCdh1. As suggested by the reviewer, we have now shown that the addition of lysine residues at positions 83 and 84 in Acm1 does not affect the extent of Acm1-Cdh1 binding by two different assays (Supplemental Figure 8 ). We have added a new experiment (Supplemental Figure 10) showing that Hsl1 K-less is a much more potent APCCdh1 inhibitor in vitro than WT Hsl1. Figure 6 . I would leave this figure out of the paper, it does not add much.
Figure 5: The authors claim that
Figure 6: If Acm1 K-less can't be purified, because it's misfolded, not much can be learned from
We agree and have removed this figure. We have struggled for a name for this motif. Since this motif is defined by the four amino acid changes in an alanine-scanning mutant, we felt we needed a shorthand way to refer to the mutant without specifying the four mutations each time. Though not an ideal name, we don't think there will be confusion between the A-motif and the A-box. (Jin et al., 2008 ). This appears to fit nicely to their lack of such sequences in pseudosubstrate inhibitors.
discussion: I think it is a bit of a stretch to call the two acidic residues involved in Cdh1 binding
The authors should add recent findings to their discussion that APC-substrates, at least in human cells, have motifs that promote the addition of the first ubiquitin
I believe that the reviewer is referring to the 'TEK' box that was discovered by Michael Rape and colleagues in higher eukaryotes (Jin et al., 2008) . However since there appears to be no conservation of these motifs in yeast APC substrates (Jin et al., 2008) , their absence from Acm1 cannot explain why Acm1 behaves as a pseudosubstrate. 
